Ken Caruso/a> submits:

As I mentioned in my earlier post I recently read One Up On Wall Street : How To Use What You Already Know To Make Money In The Market by Peter Lynch. Peter Lynch took over the Fidelity Magellan Fund in 1977 when it had $18 million in assets. When he stepped down from managing the fund in 1990 he achieved an averaged %29.2 return and the funds assets sat at $14 billion in assets.

Lynch’s investment style varies quite a bit from the traditional super value investors. Lynch seems more likely to invest in public offerings or companies that have little operating history if he feels they have potential for serious growth. Lynch is willing to take a little risk on situations where there is some uncertainty so some people might call him a “growth” investor. That being said I try to ignore categorizing investors into buckets like “growth” and “value”. Instead I categorize them into two buckets “good” and “not so good”.

Complete Story »

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5019559 for the full story.

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5018428 for the full story.

Imaging3, Inc. (IMGG), VaxGen, Inc. (VXGN), and Applied DNA Sciences Inc. (APDN) were among today’s top OTC market movers. VaxGen, Inc. (VXGN.OB: 0.769 +11.45%), which develops biologic products for the treatment of human disease, saw its shares jump more than 10 percent after its AIDSVAX – which is now held by a non-profit organization called Global [...]

Among the companies whose shares are expected to see active trade in Thursday’s session are the European airlines and Russian energy stocks as well as Amgen, Copart, Eli Lilly, McCormick, Paychex, Red Hat, Teva and Wells Fargo.

A late-stage trial combining two HIV vaccines is shown to reduce the chance of infection by a third, raising the prospects that in time AIDS can go the way of polio as an eradicated disease.